Long-term evaluation of blood silicon and ostecalcin in operatively treated patients with benign bone tumors using bioactive glass and autogenous bone.
In a study on 25 patients with verified benign bone tumors, bioactive glass (BG) and autogenous bone (AB) were used as bone-graft substitutes. The patients were randomized into two groups according to the filling material. Blood samples were taken both preoperatively, at 2 weeks, and 3, 8, 12, 24, and 36 months postoperatively, for evaluation of silicon concentration in blood. In the determination, direct current plasma atomic emission spectroscopy was used. No significant difference in blood silicon concentration between the BG group or the AB group could statistically be observed (p = 0.5400), and neither did the size of the bone tumor (p = 0.4259) nor the follow-up time affect the results (p = 0.2094). Concentration of osteocalcin in blood was significantly higher for large cysts (p < 0.0001). The filler material (BG or AB) did not affect the osteocalcin concentration level in blood.
Lindfors
N C
NC
Department of Orthopaedic and Hand Surgery, Helsinki Central University Hospital, Helsinki, Finland. nina.c.lindfors@hus.fi
Heikkilä
J T
JT
Aho
A J
AJ
D001859:Bone Neoplasms / Q000601:surgery*; D018786:Bone Substitutes / Q000737:chemistry / Q000627:therapeutic use*; D016025:Bone Transplantation; D005898:Glass; D006801:Humans; D008137:Longitudinal Studies; D008422:Materials Testing; D015675:Osteocalcin / Q000097:blood; D012825:Silicon / Q000097:blood; D055153:Stem Cell Niche / Q000473:pathology; D014182:Transplantation, Autologous
D018786:Bone Substitutes; D015675:Osteocalcin; D012825:Silicon